Sections
Shortcuts

Breast cancer drug shows ‘groundbreaking’ results

“The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies,” said Richard S. Finn (right), with Dennis Slamon at UCLA.
“The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies,” said Richard S. Finn (right), with Dennis Slamon at UCLA. 2013 file/New york times

This is a summary. To read the whole story subscribe to BostonGlobe.com

Researchers say that a new type of drug can help prevent advanced breast cancer from worsening, potentially providing an important new treatment option for women and a blockbuster product for Pfizer.

In a clinical trial, the drug cut in half the risk that cancer would worsen, or progress, researchers said Sunday. The median time before the disease progressed or the woman died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.

“The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies,” said Dr. Richard S. Finn, a principal investigator in the study. Finn, an oncologist, called the results “quite groundbreaking.”

The drug, palbociclib, also appeared to prolong survival but not by a statistically significant amount.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Sections
Shortcuts

Share